Lineage, Inc. Common Stock (LINE)vsRayonier Inc (RYN)
LINE
Lineage, Inc. Common Stock
$42.63
-1.32%
REAL ESTATE · Cap: $11.14B
RYN
Rayonier Inc
$20.97
-0.24%
REAL ESTATE · Cap: $6.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 690% more annual revenue ($5.36B vs $678.35M). RYN leads profitability with a 68.6% profit margin vs -2.7%. RYN earns a higher WallStSmart Score of 50/100 (C-).
LINE
Avoid34
out of 100
Grade: F
RYN
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Keeps 69 of every $100 in revenue as profit
Revenue surging 233.8% year-over-year
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
Elevated debt levels
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 92.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : RYN
The strongest argument for RYN centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 68.6% and operating margin at 9.4%. Revenue growth of 233.8% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : RYN
The primary concerns for RYN are Altman Z-Score, PEG Ratio, P/E Ratio. A P/E of 47.6x leaves little room for execution misses.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while RYN is a growth play — different risk/reward profiles.
RYN is growing revenue faster at 233.8% — sustainability is the question.
RYN generates stronger free cash flow (14M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RYN scores higher overall (50/100 vs 34/100), backed by strong 68.6% margins and 233.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.
Visit Website →Rayonier Inc
REAL ESTATE · REIT - SPECIALTY · USA
Rayonier is a leading timber real estate investment trust with assets located in some of the most productive softwood producing regions in the United States and New Zealand.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?